Alemtuzumab Injection (Lemtrada) is a cytolytic monoclonal antibody targeting CD52, indicated for the treatment of relapsing forms of multiple sclerosis (MS) in adults.

What Are the Purchase Channels for Alemtuzumab Injection (Lemtrada)?

Overseas Purchase

Patients can choose to consult and purchase the drug at hospital pharmacies or licensed pharmacies in countries/regions where alemtuzumab injection has been approved for marketing.

As drug prices may be affected by regional differences, exchange rate fluctuations and other factors, patients need to make a budget and plan before purchasing.

Purchase via Medical Service Institutions

Patients can consult domestic overseas medical service institutions that cooperate with international pharmacies or pharmaceutical companies.

These institutions can usually provide legal import channels as well as professional consultation and guidance.

Precautions for the Administration of Alemtuzumab Injection (Lemtrada)

Baseline Screening and Contraindication Exclusion

Laboratory Tests: Before administration, it is necessary to complete full blood count with differential, serum creatinine, urine routine with cell count, thyroid function tests, etc.

Absolute Contraindications: The drug is contraindicated in patients with hypersensitivity to alemtuzumab, HIV infection, or active infections.

Infusion Safety and Emergency Preparedness

Facility Requirements: Infusion must be performed in medical facilities equipped with emergency equipment and staff proficient in emergency response procedures.

Monitoring Standards: Continuous monitoring for at least 2 hours after each infusion is required to guard against delayed infusion reactions.

Early Identification and Intervention of Complications

Autoimmune Disease Monitoring: Focus on the risks of thyroid disorders (36.8%), immune thrombocytopenia (2%), glomerulonephritis (0.3%), etc.

Authenticity Identification of Alemtuzumab Injection (Lemtrada)

Verification of Packaging and Label Specifications

Drug Information: Legitimate alemtuzumab injection is packaged in single-dose vials (12mg/1.2mL), and the label must clearly indicate the active ingredient (alemtuzumab), concentration (10mg/mL), and complete production information.

Physical Characteristics: The drug is a colorless to slightly yellow transparent liquid without suspended particles or precipitates. If turbidity, discoloration, or flocculent substances appear, the drug should be immediately discontinued and reported.

Channel Traceability and Qualification Verification

Medical Institution Certification: Check the list of certified institutions through the alemtuzumab injection REMS program.